A simple blood test that measures the number of lymphocytes may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy.
A new preclinical model offers a unique platform for studying the Parkinson’s disease process and suggests a relatively easy method for detecting the disease.
Weill Cornell Medicine has received $4.2 million to study how the immune system in some people infected with HIV can keep the virus under control, which could lead to new therapies.
Researchers at Weill Cornell Medicine have used machine learning to define three subtypes of Parkinson’s disease based on the pace at which the disease progresses.
A new consortium co-led by Weill Cornell Medicine has been awarded a five-year, $31 million grant from the NIH’s National Institute of Allergy and Infectious Diseases to accelerate the development of better treatment regimens for tuberculosis.
Scientists from Weill Cornell Medicine and the Dana-Farber Cancer Institute have developed new AI tools tailored to digital pathology, a growing field that uses high-resolution digital images created from tissue samples to help diagnose disease.
Vaccinating mothers against RSV during late pregnancy to protect their newborns is not associated with an increased risk of preterm birth or other poor outcomes, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.
Designed to provide corporate leaders with critical skills and actionable insights to bring to their boardrooms, the 2024 Cornell Tech Board of Directors Forum is slated for Oct. 29 and 30 in New York City.
Before a cell commits fully to the process of dividing itself into two new cells, it may ensure the appropriateness of its commitment by staying for many hours – sometimes more than a day – in a reversible intermediate state, according to new research.
